APA (7th ed.) Citation

Mu, C., Shen, J., Zhu, X., Peng, W., Zhang, X., & Wen, T. (2023). The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: A case series report. Frontiers in oncology, 13, 1096955. https://doi.org/10.3389/fonc.2023.1096955

Chicago Style (17th ed.) Citation

Mu, Chunyang, Junyi Shen, Xinrui Zhu, Wei Peng, Xiaoyun Zhang, and Tianfu Wen. "The Efficacy and Safety of Lenvatinib Plus Transarterial Chemoembolization in Combination with PD-1 Antibody in Treatment of Unresectable Recurrent Hepatocellular Carcinoma: A Case Series Report." Frontiers in Oncology 13 (2023): 1096955. https://doi.org/10.3389/fonc.2023.1096955.

MLA (9th ed.) Citation

Mu, Chunyang, et al. "The Efficacy and Safety of Lenvatinib Plus Transarterial Chemoembolization in Combination with PD-1 Antibody in Treatment of Unresectable Recurrent Hepatocellular Carcinoma: A Case Series Report." Frontiers in Oncology, vol. 13, 2023, p. 1096955, https://doi.org/10.3389/fonc.2023.1096955.